Write a short notes on origin and evaluation of pharmaco economics for 14 marks
Reading File
Searching the Web
origin and evolution of pharmacoeconomics history development
Finding Sources
Reading Web Page
origin and evolution history of pharmacoeconomics
I now have comprehensive material. Let me compile a well-structured, exam-ready 14-mark short notes answer.
Origin and Evolution of Pharmacoeconomics
1. Definition
Pharmacoeconomics is a scientific discipline that identifies, measures, and compares the costs (resources consumed) and consequences (clinical, economic, humanistic) of pharmaceutical products and services. It is a sub-discipline of health economics focused on guiding optimal allocation of healthcare resources.
More specifically, pharmacoeconomic research evaluates costs, risks, and benefits of drug therapy programs to determine which alternative produces the best health outcome for the resource invested.
2. Origin - Conceptual Roots
The origins of pharmacoeconomics lie at the intersection of two developments:
a) Rise of Health Economics
- Classical economics had minimal application to healthcare until the mid-20th century.
- Early economic evaluations of health programs in the 1950s-60s measured the value of improved health crudely - largely as increased labour productivity.
- The first book on health economics was published in 1973 by Cooper MH, marking the beginning of a formal discipline.
b) Clinical Pharmacy Movement
- In the early 1960s, pharmacy was formally recognized as a clinical discipline within healthcare.
- Subjects like clinical pharmacy, drug information, and pharmacokinetics entered pharmacy education.
- The Pharm.D. (Doctor of Pharmacy) program, introduced in the 1950s in the USA, created a generation of pharmacists who viewed drug therapy in terms of outcomes - setting the intellectual groundwork for pharmacoeconomics.
3. Evolution - Key Milestones
Phase 1: Academic Foundation (1970s)
| Year | Milestone |
|---|---|
| 1970s | Pharmacoeconomics developed its conceptual roots, primarily in the USA |
| 1973 | First textbook on health economics published (Cooper MH) |
| 1976 | McGhan, Rowland, and Bootman introduced pharmacoeconomic concepts at the University of Minnesota |
| 1978 | Formal introduction of cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA) in pharmacy by McGhan, Rowland & Bootman (University of Minnesota) |
| 1979 | Bootman et al. published a landmark study using CBA with pharmacokinetic protocols to evaluate individualized aminoglycoside dosing in severely burned patients with gram-negative septicemia - one of the first applied pharmacoeconomic studies |
Phase 2: Formalization (1980s)
| Year | Milestone |
|---|---|
| 1983 | Ohio State University College of Pharmacy launched a dedicated pharmacoeconomics academic curriculum - the first of its kind - focusing on CBA and CEA application to pharmaceutical care |
| 1986 | Ray Townsend from the Upjohn Company coined the term "pharmacoeconomics" for the first time in a public forum at a pharmacists' meeting in Toronto, Canada. His published work also formally defined the discipline and called for structured research. This is considered the birth of modern pharmacoeconomics as a named field. |
Phase 3: Institutionalization (1990s)
| Year | Milestone |
|---|---|
| 1992 | The journal "Pharmacoeconomics" was launched, providing a dedicated peer-reviewed platform |
| 1993 | Australia became the first country in the world to mandate pharmacoeconomic analysis for drug reimbursement decisions. The Pharmaceutical Benefits Advisory Committee (PBAC) required cost-effectiveness data before subsidizing new drugs. |
| 1990s | Canada, Finland, New Zealand, Norway, Sweden, and the UK adopted similar models |
| 1995 | ISPOR (International Society for Pharmacoeconomics and Outcomes Research) was established, giving the field a global professional body |
Phase 4: Modern Era (2000s - Present)
- Quality-Adjusted Life Year (QALY) became the dominant outcome measure in pharmacoeconomic evaluations.
- Health Technology Assessment (HTA) bodies (UK's NICE, Canada's CADTH, etc.) embedded pharmacoeconomics in national drug pricing and formulary decisions.
- Pharmacoeconomic modeling - decision trees, Markov models, and budget impact analysis - became standard research tools.
- In developing countries including India, pharmacoeconomics gained prominence given scarce resources and the need for rational drug therapy programs.
4. Need for Pharmacoeconomics
The evolution of pharmacoeconomics was driven by practical pressures:
- Escalating drug costs - e.g., gene therapies costing $750,000-$850,000 per year per patient.
- Limited healthcare budgets forcing payers to demand value-for-money evidence.
- Formulary decision-making - hospitals and insurers needed objective tools to select drugs.
- Drug policy development - governments needed frameworks to decide subsidy eligibility.
- Regulatory requirements - many countries now require pharmacoeconomic dossiers alongside clinical trial data for drug approval and reimbursement.
5. Summary Timeline
1950s → Pharm.D. programs launched (USA)
1960s → Clinical pharmacy recognized as discipline
1973 → First health economics textbook
1978 → CBA/CEA introduced in pharmacy (Univ. Minnesota)
1979 → First applied pharmacoeconomic study (aminoglycosides)
1983 → First dedicated PE curriculum (Ohio State Univ.)
1986 → Term "pharmacoeconomics" coined (Ray Townsend, Toronto)
1992 → Journal "Pharmacoeconomics" launched
1993 → Australia mandates PE for drug reimbursement (world-first)
1995 → ISPOR established
2000s+ → QALY, HTA, Markov modeling, global policy integration
6. Conclusion
Pharmacoeconomics emerged from the convergence of health economics, clinical pharmacy, and outcomes research in the 1970s. From its academic origins at the University of Minnesota to its naming by Ray Townsend in 1986 and its policy adoption by Australia in 1993, the field has grown into a global discipline that informs drug pricing, formulary management, reimbursement decisions, and healthcare resource allocation worldwide. It represents the formal mechanism by which the value of drug therapy is measured and compared.
Sources: IJPREMS (2024); Tishk International University Lecture Notes on Pharmacoeconomics; Wikipedia - Pharmacoeconomics; ACCP Pharmacoeconomics Reference Chapter; Cooper MH (1973) - First Health Economics Text.
This is a shared conversation. Sign in to Orris to start your own chat.